Taxol is a powerful anti-cancer drug that strongly binds to the ␤-subunit of tubulin and promotes the formation of highly stable microtubules that resist depolymerization, thus preventing active tumour cell division and arresting the cells at the G2/M phase of the cell cycle [8, 9] . Taxol induces apoptosis in cancer cells through activation of caspase pathways [6, 10] . Although [11] . Up [12, 13] 
-regulation of the anti-apoptotic Bcl-2 molecule in tumour cells prevents cell death due to inhibition of mitochondrial release of cytochrome c into the cytosol and thereby exerts a survival advantage to tumour cells in response to various apoptotic stimuli

. Introduction of Bcl-2 siRNA into tumour cells through a plasmid vector could degrade Bcl-2 mRNA and thus down-regulate the cognate protein level. Therefore, treatment with the combination of a low dose of taxol and a plasmid vector carrying the Bcl-2 siRNA cDNA could be an innovative therapeutic strategy to inhibit cell division and induce apoptosis in glioblastoma cells
This investigation was designed to use a low dose of taxol and knockdown the expression of Bcl-2 using a gene specific siRNA for efficiently induction of apoptosis in highly invasive human glioblastoma cells and also inhibition of cell invasion, in vivo angiogenesis and both intracranial and subcutaneous tumourigenesis in athymic nude mice. 
Materials and methods
Cell culture conditions
In vitro matrigel invasion assay
In vitro Matrigel invasion assay [15] 
In vivo angiogenesis (dorsal skinfold) assay
Anti-angiogenic effect of taxol and Bcl-2 siRNA in U251MG cells was examined using the in vivo angiogenesis (dorsal skinfold) assay [16] 
Bioluminescence imaging of intracerebral and subcutaneous tumours in nude mice
We have selected the U251MG cells for further in vivo studies because it is one of the most invasive and virulent cell line among all human glioblastoma cell lines. The U251MG cells were stably transfected with a plasmid vector (phCMV-FSR, Genlantis, San Diego, CA, USA) carrying luciferase gene and propagated in media containing G-418 (500 g/ml
Increased expression of active fragments of caspase-9 and caspase-3
Double immunofluorescent staining was employed to examine the active fragments (cleaved subunits) of caspase-9 and caspase-3 (Fig. 3). We used specific antibodies for the active fragments to avoid cross-reaction with the parent molecules. Immunofluorescent stainings demonstrated remarkable increases in the active fragments of caspase-9 and caspase-3 after treatments with taxol, Bcl-2 siRNA and both agents together (Fig. 3A). The stainings were highly conspicuous after treatment of cells with combination of taxol and Bcl-2 siRNA. Counterstaining of the nucleus with Hoechst 33342 revealed nuclear fragmentation in cells treated with taxol, Bcl-2 siRNA and combination of both. Merged microphotographs clearly demonstrated simultaneous stainings of active fragments of caspase-9 and caspase-3 as well as of
Fig. 3 In situ stainings for biochemical markers of apoptosis in U251MG cells. Treatment (72 hrs) of cells: transfection with a plasmid vector expressing scrambled siRNA (treated control), 100 nM taxol, transfection with a plasmid vector expressing Bcl-2 siRNA and taxol ϩ Bcl-2 siRNA. (A) Double immunofluorescent stainings to examine active fragments of caspase-9 and caspase-3. The cells were incubated overnight at 4ЊC with specific antibodies for active fragments of caspase-9 and caspase-3, washed and then treated with FITC conjugated and Texas red conjugated secondary antibodies at room temperature for 1 hr. Hoechst 33342 was used to counterstain the nucleus. Merged microphotographs demonstrated simultaneous expression of active fragments of caspase-9 and caspase-3 as well as disintegration of nucleus in the apoptotic cells (shown with arrows). (B) Fluorescent TUNEL assay for detection of apoptotic cells. Treatment with combination of taxol and Bcl-2 siRNA resulted in more apoptotic cell death than either treatment alone. (C) Quantitation of TUNEL-positive cells. Data are representative of four independent experiments (*P Ͻ 0.001 when compared with the scrambled siRNA treatment mean values and #P Ͻ 0.001 when compared with taxol or Bcl-2 siRNA treatment mean values). disintegrating nucleus in the apoptotic cells (shown with arrows
Marked reduction in tumour cell invasion
We examined the effects of taxol, Bcl-2 siRNA and combination of both agents on the invasive properties of both U138MG and U251MG cells using the Matrigel invasion assay (Fig. 4) (Fig. 4B) . In U251MG cells, we observed only 35%, 49% and 10% invasion after treatment with taxol, Bcl-2 siRNA and both agents together, respectively (Fig. 4D) . The scrambled siRNA treatments were considered as treated controls for both cell lines.
Inhibition of in vivo angiogenesis
We examined the effect of taxol, Bcl-2 siRNA and both agents together on in vivo angiogenesis in terms of neovascularization in the dorsal skin of nude mice (Fig. 5) (Fig. 6 ). 
Inhibition of intracranial tumour growth in nude mice
We injected cell suspensions of U251MG untreated control cells, cells transfected with scrambled Bcl-2 siRNA (treated control) and cells treated with either taxol or Bcl-2 siRNA or both agents together, into the cerebrum of nude mice and allowed them to grow for 3 weeks (Fig. 6). All animals were scanned using bioluminescence imaging to examine the changes in tumour growth on days 7, 14 and 21 (Fig. 6). The implantations of untreated control cells and cells transfected with scrambled siRNA resulted in similar rate of cell multiplication and tumourigenesis as indicated by the large bioluminescence image produced by the tumour cells carrying a luciferase gene
Combination of taxol and Bcl-2 siRNA inhibited subcutaneous tumourigenesis and solid tumour development in nude mice
Further, we examined the effects of taxol or/and Bcl-2 siRNA on U251MG cells for capability of subcutaneous tumourigenesis and solid tumour development in nude mice (Fig. 7) . The capability of U251MG cells for subcutaneous tumourigenesis was remarkably inhibited after treatment with combination of taxol and Bcl-2 siRNA (Fig. 7A ). The mice with control and scrambled siRNA treated U251MG cells produced almost similar well-developed solid tumours in a 6-week period (Fig 7B) the most remarkable reduction in solid tumour growth (Fig 7B) . The longitudinal measurements of solid tumour volume revealed steady state growth in animals with control and scrambled siRNA vector transfected U251MG cells (Fig. 7C) . The tumour growth curve switched significantly downhill after treatment with taxol or Bcl-2 siRNA and it did not rise and remained almost straight after treatment with combination of taxol and Bcl-2 siRNA (Fig. 7C) . Moreover, measurements of tumour weight demonstrated 59% and 61% reduction in tumour weight after treatments with taxol alone and Bcl-2 siRNA alone, respectively (Fig. 7D) . Most importantly, treatment with combination of taxol and Bcl-2 siRNA resulted in 94% reduction in tumour weight (Fig. 7D) . These results confirmed that combination of taxol and Bcl-2 siRNA was the most effective treatment for inhibition of subcutaneous tumourigenesis and solid tumour development in nude mice.
Discussion
Taxol is one of the most powerful anti-cancer drugs that strongly bind to ␤-tubulin to prevent tumour cell division and induce cell death [18, 19] . [20, 21] [25] . During tumourigenesis, angiogenesis depends on the production of a variety of pro-angiogenic molecules including vascular endothelial growth factor (VEGF) by tumour cells [26] . It is now known that VEGF plays a key role in angiogenesis and tumour cell metastasis [27, 28] . Up-regulation of VEGF in various tumours, especially in malignant brain tumours [26] [22] . Silencing of Bcl-2 and Bcl-xL genes in conjunction with chemotherapy provided a potential therapeutic strategy against human hepatoblastoma [30] . Furthermore, downregulation of Bcl-2 and XIAP using gene silencing technology in human breast cancer MCF-7 cells has been shown to enhance the effects of etoposide and doxorubicin for increasing apoptosis and reducing cell growth [23] .
Gene silencing through intraperitoneal injection of plasmid vector carrying the siRNA cDNA is an effective method [11] . Recently, it has also been demonstrated that intraperitoneal injection of a hairpin RNA-expressing plasmid vector targeting urokinase-type plasminogen activator receptor can retard angiogenesis and inhibit intracranial tumour growth in nude mice [31] . In addition, intraperitoneal injections of DY547 and rhodamine-labelled siRNA showed strong signals in the liver, spleen and bone marrow [32] . 
